Givaudan in the news

Swiss stocks rise slightly with Nestlé and Givaudan among leaders, while Alcon and Geberit fall on weak earnings; investors await US Fed signals.

Givaudan's stock is trading lower, significantly below its 52-week high, with dividends and earnings estimates indicating steady financial performance.

Givaudan's stock is performing well, currently up 0.3% and showing potential for growth.

Givaudan is building a large, automated fragrance production plant and creative center in Guangzhou, relocating 150 employees over two years.

Givaudan targets higher organic growth and expansion into biotech and wellness sectors with strong innovation and ESG commitments through 2030.

Givaudan's CEO Gilles Andrier will retire in 2026 after growing the company significantly, with Christian Stammkoetter named as his successor.

Givaudan's revenue grew 3.4% to 3.86 billion CHF in H1, with 6.3% organic growth.

Swiss market dipped slightly with Givaudan shares up amid investor confidence, while political and economic uncertainties weigh on broader markets.

Givaudan intends to acquire US perfume maker Belle Aire Creations, which earned 65 million CHF in 2024, with the deal closing by 2025 or 2026.

Berenberg cut Givaudan's price target and forecasts due to planned investments and weak market conditions across its global flavor and fragrance business.

Givaudan continues stable growth with strong innovation and market position, while other Swiss companies like Kardex, Avolta, and Emmi show varied growth and valuation dynamics.

European stocks fell with Givaudan and Akzo Nobel pressured by weaker-than-expected quarterly results and cautious market sentiment.

Givaudan's long-serving CEO Andrier plans a sensitive transition to chairman, raising corporate governance concerns.

Givaudan's sales continued to grow in Q1 2024, following a record year.

Givaudan is investing 40 million CHF to build a new automated fragrance plant and creative center in Guangzhou, expanding its presence in China as part of its 2030 growth strategy.

Givaudan opened a biotechnology innovation center in Toulouse to boost R&D for beauty ingredients.

UBS raised Givaudan's price target and earnings forecasts but kept a neutral rating, highlighting its strong position in luxury perfumes.

Givaudan's stock showed a slight increase with positive dividend and earnings forecasts ahead of upcoming financial reports.

Givaudan's stock declined slightly during trading, remains below its yearly high, and is set to report Q4 2025 results in January 2026.

Givaudan's stock dropped 0.5% midday, trading below its 52-week high, with analysts expecting higher dividends and strong 2025 earnings.